Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm, cytosol. Cell membrane. Golgi apparatus membrane. Note=Recruited to plasma membrane by activated HRAS and RAP2. Recruited to perinuclear membrane by activated RAP1A. Isoform 1 and isoform 2 associates with Golgi membranes. |
Domain |
PF00168 C2 domain PF09279 Phosphoinositide-specific phospholipase C PF00388 Phosphatidylinositol-specific phospholipase C PF00387 Phosphatidylinositol-specific phospholipase C PF00788 Ras association (RalGDS/AF-6) domain PF00617 RasGEF domain |
Function |
The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. PLCE1 is a bifunctional enzyme which also regulates small GTPases of the Ras superfamily through its Ras guanine-exchange factor (RasGEF) activity. As an effector of heterotrimeric and small G-protein, it may play a role in cell survival, cell growth, actin organization and T-cell activation. |
Biological Process |
GO:0000187 activation of MAPK activity GO:0001558 regulation of cell growth GO:0001655 urogenital system development GO:0001822 kidney development GO:0003012 muscle system process GO:0006066 alcohol metabolic process GO:0006638 neutral lipid metabolic process GO:0006639 acylglycerol metabolic process GO:0006644 phospholipid metabolic process GO:0006651 diacylglycerol biosynthetic process GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006936 muscle contraction GO:0006937 regulation of muscle contraction GO:0006939 smooth muscle contraction GO:0006940 regulation of smooth muscle contraction GO:0007173 epidermal growth factor receptor signaling pathway GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0007205 protein kinase C-activating G-protein coupled receptor signaling pathway GO:0007265 Ras protein signal transduction GO:0007507 heart development GO:0008277 regulation of G-protein coupled receptor protein signaling pathway GO:0016042 lipid catabolic process GO:0016049 cell growth GO:0019722 calcium-mediated signaling GO:0019751 polyol metabolic process GO:0019932 second-messenger-mediated signaling GO:0032147 activation of protein kinase activity GO:0032835 glomerulus development GO:0033674 positive regulation of kinase activity GO:0038127 ERBB signaling pathway GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043647 inositol phosphate metabolic process GO:0044057 regulation of system process GO:0045017 glycerolipid biosynthetic process GO:0045860 positive regulation of protein kinase activity GO:0046339 diacylglycerol metabolic process GO:0046460 neutral lipid biosynthetic process GO:0046463 acylglycerol biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046578 regulation of Ras protein signal transduction GO:0048016 inositol phosphate-mediated signaling GO:0051056 regulation of small GTPase mediated signal transduction GO:0051480 regulation of cytosolic calcium ion concentration GO:0055074 calcium ion homeostasis GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0072001 renal system development GO:0072006 nephron development GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0090257 regulation of muscle system process GO:1901615 organic hydroxy compound metabolic process |
Molecular Function |
GO:0004435 phosphatidylinositol phospholipase C activity GO:0004620 phospholipase activity GO:0004629 phospholipase C activity GO:0005057 receptor signaling protein activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0008081 phosphoric diester hydrolase activity GO:0016298 lipase activity GO:0017016 Ras GTPase binding GO:0031267 small GTPase binding GO:0042578 phosphoric ester hydrolase activity GO:0051020 GTPase binding |
Cellular Component | - |
KEGG |
hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04020 Calcium signaling pathway hsa04024 cAMP signaling pathway hsa04070 Phosphatidylinositol signaling system hsa04919 Thyroid hormone signaling pathway hsa00562 Inositol phosphate metabolism hsa01100 Metabolic pathways |
Reactome |
R-HSA-1483249: Inositol phosphate metabolism R-HSA-1430728: Metabolism R-HSA-1855204: Synthesis of IP3 and IP4 in the cytosol |
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PLCE1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PLCE1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PLCE1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of PLCE1 in various data sets.
|
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLCE1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLCE1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLCE1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLCE1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PLCE1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PLCE1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PLCE1 |
Name | phospholipase C, epsilon 1 |
Aliases | KIAA1516; NPHS3; nephrosis type 3; PPLC; PLC-epsilon-1; pancreas-enriched phospholipase C; phosphoinositide ...... |
Chromosomal Location | 10q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PLCE1 collected from DrugBank database. |
There is no record. |